"Verve Therapeutics' experimental gene-editing drug VERVE-102 showed positive early results in a 35-patient Phase I trial. The drug targets PCSK9 to lower LDL cholesterol with a single infusion. Participants showed up to 62% reduction in LDL cholesterol at the highest dose."